stockrowVir Biotechnology, Inc.
VIRVir Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $68.6 million, down 7.61% from fiscal 2024.
- Revenue
- −178.3%
- EPS
- +51.4%
- Free cash flow
- +36.8%
Quarter to September 2026, against a year earlier
Follow VIR
Alert me
Vir Biotechnology, Inc. (VIR) Return on invested capital
Vir Biotechnology, Inc.'s return on invested capital over the twelve months to 30 September 2026 was −30.3%, up 70.8 percentage points from fiscal 2025 (−101.1%). Over the past ten years it has ranged from −783.9% (fiscal 2023) to 36.8% (fiscal 2021); the current reading is higher than 44% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −101.1% | 134.68 |
| FY2024 | −235.8% | 548.13 |
| FY2023 | −783.9% | (783.90) |
| FY2022 | 0.00% | (36.77) |
| FY2021 | 36.8% | 36.77 |
| FY2020 | 0.00% | 324.07 |
| FY2019 | −324.1% | (324.07) |
| FY2018 | 0.00% | 0.00 |
| FY2017 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| ZYME Zymeworks Inc. compare | 17.5% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.00% |
| IMNM Immunome, Inc. compare | 0.00% |
| TRAX First Tracks Biotherapeutics, Inc. compare | 0.00% |
| VIR Vir Biotechnology, Inc. | −30.3% |
| RXRX Recursion Pharmaceuticals, Inc. compare | −88.5% |
| REPL Replimune Group, Inc. compare | −928.3% |
| BHVN Biohaven Ltd. compare | −6,659.9% |
| NAMS NewAmsterdam Pharma Company N.V. compare | −13,975.8% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on VIR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement